Supernus Pharmaceuticals (NASDAQ: SUPN) CEO granted 29,849 performance share units

Rhea-AI Filing Summary

Supernus Pharmaceuticals reported that President and CEO Jack A. Khattar acquired 29,849 Performance Share Units on July 29, 2026, at $0.00 per unit. Each unit corresponds to one share of common stock, leaving him holding 29,849 such units from this award after the transaction.

The Performance Share Units were originally awarded on February 19, 2025, with a portion vesting upon the achievement of individual performance objectives that were established on May 3, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Khattar Jack A.

Role President, CEO

Type	Security	Shares	Price	Value
Grant/Award	Performance Share Unit F1	29,849	$0.00	$0.00

Holdings After Transaction: Performance Share Unit — 29,849 shares (Direct)

Footnotes (1)

1. F1. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Key Figures

Performance Share Units acquired: 29849.0000 units Underlying common stock: 29849.0000 shares Grant price per unit: 0.0000 +3 more

6 metrics

Performance Share Units acquired 29849.0000 units Grant/award acquisition reported on July 29, 2026

Underlying common stock 29849.0000 shares Each Performance Share Unit corresponds to one share of common stock

Grant price per unit 0.0000 Performance Share Units granted at $0.00 per unit as equity compensation

Units held after transaction 29849.0000 units Total Performance Share Units from this award following the reported acquisition

Original award date February 19, 2025 Date the Performance Share Units were initially awarded to the reporting person

Performance objectives set May 3, 2025 Date individual performance objectives for the award were established

Key Terms

Performance Share Unit, underlying security, Rule 10b5-1

3 terms

Performance Share Unit financial

"security title "Performance Share Unit" granted to the reporting person"

A performance share unit (PSU) is a form of executive or employee pay that promises shares (or the cash value of shares) only if the company meets specific performance targets over a set period. Think of it like a bonus cheque that only arrives if the company hits agreed goals — it aligns managers’ rewards with business results and signals to investors how leadership is being incentivized to grow value over time.

underlying security financial

"underlying security title listed as "Common Stock" for the units"

Rule 10b5-1 financial

"document-level checkbox indicates Rule 10b5-1 trading plan status"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/31/2026 - 05:07 PM Accepted by SEC EDGAR 07/31/2026 - 05:06 PM Learn about SEC filing dates

FAQ

What insider transaction did SUPN disclose for CEO Jack A. Khattar?

SUPN disclosed that CEO Jack A. Khattar acquired 29,849 Performance Share Units on July 29, 2026. These units were granted at $0.00 per unit and each corresponds to one share of Supernus common stock upon settlement, representing equity-based compensation.

How many performance share units did the SUPN CEO receive in this Form 4?

The SUPN CEO received 29,849 Performance Share Units in this reported transaction. After the acquisition, he holds 29,849 units from this award, each linked to one underlying share of Supernus Pharmaceuticals common stock, subject to the plan’s vesting and settlement terms.

What is the relationship between the SUPN performance share units and common stock?

Each reported Performance Share Unit for SUPN corresponds to one share of common stock. In this filing, the 29,849 units are tied to 29,849 underlying common shares, which may be delivered upon satisfaction of applicable vesting and settlement conditions specified in the award.

When were the SUPN CEO’s performance objectives for these units established?

For this SUPN award, individual performance objectives were established on May 3, 2025. The Performance Share Units were awarded on February 19, 2025, and a portion vested upon achievement of those objectives within a defined performance period, as described in the footnote.

Was the SUPN CEO’s performance share unit transaction under a Rule 10b5-1 plan?

The transaction was not reported as being under a Rule 10b5-1 trading plan. The Form 4’s specific checkbox indicating Rule 10b5-1 status is not marked as affirmed, and the related footnote does not reference any pre-arranged trading plan.

What was the price per unit for the SUPN CEO’s performance share unit award?

The Performance Share Units for SUPN’s CEO were granted at $0.00 per unit. This reflects that the award is a form of equity compensation rather than a market purchase, with value dependent on Supernus common stock and meeting the performance and vesting conditions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khattar Jack A.

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	$0	07/29/2026		A		29,849		(1)	(1)	Common Stock	29,849	$0	29,849	D

Explanation of Responses:

1. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)